243 related articles for article (PubMed ID: 30640711)
21. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
[TBL] [Abstract][Full Text] [Related]
22. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
23. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
Nomura Y; Shirouzu M; Takayama T
Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
[TBL] [Abstract][Full Text] [Related]
24. In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.
Chen JL; Chang CJ; Wang JY; Wen CS; Tseng LM; Chang WC; Noomhorm N; Liu HJ; Chen WS; Chiu JH; Shyr YM
Integr Cancer Ther; 2014 May; 13(3):226-39. PubMed ID: 24525674
[TBL] [Abstract][Full Text] [Related]
25. Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations.
Naundorf H; Jost-Reuhl B; Becker M; Reuhl T; Neumann C; Fichtner I
Breast Cancer Res Treat; 2000 Mar; 60(1):81-92. PubMed ID: 10845812
[TBL] [Abstract][Full Text] [Related]
26. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Cheng R; Liu YJ; Cui JW; Yang M; Liu XL; Li P; Wang Z; Zhu LZ; Lu SY; Zou L; Wu XQ; Li YX; Zhou Y; Fang ZY; Wei W
Oncotarget; 2017 May; 8(18):30252-30264. PubMed ID: 28415819
[TBL] [Abstract][Full Text] [Related]
27. Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats.
Zhang X; Cook KL; Warri A; Cruz IM; Rosim M; Riskin J; Helferich W; Doerge D; Clarke R; Hilakivi-Clarke L
Clin Cancer Res; 2017 Feb; 23(3):814-824. PubMed ID: 28148690
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.
Brechbuhl HM; Finlay-Schultz J; Yamamoto TM; Gillen AE; Cittelly DM; Tan AC; Sams SB; Pillai MM; Elias AD; Robinson WA; Sartorius CA; Kabos P
Clin Cancer Res; 2017 Apr; 23(7):1710-1721. PubMed ID: 27702820
[No Abstract] [Full Text] [Related]
29. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
[TBL] [Abstract][Full Text] [Related]
30. [Mechanism of acquired antiestrogen resistance and its management in breast cancer].
Iino Y; Maemura M; Morishita Y
Nihon Rinsho; 1997 May; 55(5):1149-54. PubMed ID: 9155167
[TBL] [Abstract][Full Text] [Related]
31. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
33. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
34. Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a-anthracene-induced rat mammary tumors in relation to hormone receptors.
Tominaga T; Yoshida Y; Kitamura M; Kosaki G
Jpn J Cancer Res; 1985 Nov; 76(11):1120-5. PubMed ID: 2935517
[TBL] [Abstract][Full Text] [Related]
35. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
McDougal A; Wormke M; Calvin J; Safe S
Cancer Res; 2001 May; 61(10):3902-7. PubMed ID: 11358803
[TBL] [Abstract][Full Text] [Related]
37. Binding sites of droloxifene in the cytosol of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Kawamura I; Lacey E; Tanaka Y; Nishigaki F; Manda T; Shimomura K
Jpn J Cancer Res; 1994 Jun; 85(6):639-44. PubMed ID: 8063618
[TBL] [Abstract][Full Text] [Related]
38. Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors.
Martin G; Melito G; Rivera E; Levin E; Davio C; Cricco G; Andrade N; Caro R; Bergoc R
Cancer Lett; 1996 Feb; 100(1-2):227-34. PubMed ID: 8620446
[TBL] [Abstract][Full Text] [Related]
39. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
40. New approaches to the understanding of tamoxifen action and resistance.
Berstein LM; Zheng H; Yue W; Wang JP; Lykkesfeldt AE; Naftolin F; Harada H; Shanabrough M; Santen RJ
Endocr Relat Cancer; 2003 Jun; 10(2):267-77. PubMed ID: 12790788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
